Pharmaceutical - AstraZeneca, Antibiotics and Infectious diseases


Popular Filters

EMA advisory unit issues bunch of positive recommendations

EMA advisory unit issues bunch of positive recommendations


At its late November meetings, the European Medicines Agency’s Committee for Medicinal Products for…

AB ScienceAnti-viralsAntibiotics and Infectious diseasesAstraZenecaBristol-Myers SquibbDeltybaDiabetesEuropeGilead SciencesLucaneLucane PharmaMasicanOncologyOtsukaPharmaceuticalRegulationSovaldiTivicayViiV HealthcareXigduo

A*STAR and AstraZeneca link to combat Gram-negative bacterial infections

A*STAR and AstraZeneca link to combat Gram-negative bacterial infections


Two units under Singapore’s Agency for Science, Technology and Research (A*STAR) have signed a joint…

A*STARAntibiotics and Infectious diseasesAstraZenecaPharmaceuticalResearch

Antibiotic ceftaroline fosamil shows promise for treating MRSA pneumonia


A drug approved just two years ago for treating bacterial infections may hold promise for treating the…

Antibiotics and Infectious diseasesAstraZenecaceftaroline fosamilForest LaboratoriesPharmaceuticalResearchTeflaroZinforo

AstraZeneca's Brilinta gains Class I in ACCF/AHA Guidelines; enters deal with Progenics


Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced yesterday that a combined panel of experts…

Antibiotics and Infectious diseasesAstraZenecaBrilintaCardio-vascularLicensingMedImmunePharmaceuticalProgenics PharmaceuticalsRegulation

AstraZeneca inks deal for Optimer's fidaxomicin in Latin America


USA-based Optimer Pharmaceuticals (Nasdaq: OPTR) says it has executed an exclusive agreement with Anglo-Swedish…

Antibiotics and Infectious diseasesAstraZenecafidaxomicinLicensingOptimer PharmaceuticalsPharmaceuticalSouth America

AstraZeneca gains rights to Ardelyx program; GSK returns cUTI candidate GSK2251052 to Anacor


Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning announced a worldwide exclusive licensing…

Anacor PharmaceuticalAntibiotics and Infectious diseasesArdelyxAstraZenecaGastro-intestinalsGenito-urinaryGlaxoSmithKlineGSK2251052LicensingNephrology and HepatologyPharmaceuticalRDX5791Research

Pharmaceutical majors unite in Japan to combat H. pylori


On August 31, nine pharmaceutical companies operating in Japan (Kyowa Hakko Kirin, Takeda Pharmaceutical,…

Antibiotics and Infectious diseasesAsia-PacificAstraZenecaGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

AstraZeneca poaches Roche exec as CEO; Gets EU approval for Zinforo


Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning revealed that Pascal Soriot from rival Switzerland-based…

Antibiotics and Infectious diseasesAstraZenecaEuropeManagementPharmaceuticalRegulationRocheZinforo

AstraZeneca/BTG abandon CytoFab for sepsis as it fails in Ph IIb


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has decided to halt any further development of AZD9773…

Antibiotics and Infectious diseasesAstraZenecaBTGCytoFabLicensingPharmaceuticalResearch

News briefs: TB drug developments at Jansen and AstraZeneca; NPS/Amgen deal amended


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Research & Development unit has submitted…

AmgenAntibiotics and Infectious diseasesAstraZenecabedaquilineBiotechnologyCellworkscinacalcetJanssenJohnson & JohnsonLicensingMetabolicsNPS PharmaceuticalsPharmaceuticalRegulationResearch

AstraZeneca and Forest initiate Ph III trials of CAZ-AVI


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and USA-based Forest Laboratories (NYSE: FRX) said this…

Antibiotics and Infectious diseasesAstraZenecaavibactamCeftazidimeForest LaboratoriesPharmaceuticalResearch

Back to top